CoChat

Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma

Chicard, Mathieu, Colmet-Daage, Leo, Clement, Nathalie, Danzon, Adrien, Bohec, Mylène, Bernard, Virginie, Baulande, Sylvain, Bellini, Angela, Deveau, Paul, Pierron, Gaëlle, Lapouble, Eve, Janoueix-Lerosey, Isabelle, Peuchmaur, Michel, Corradini, Nadège, Defachelles, Anne Sophie, Valteau-Couanet, Dominique, Michon, Jean, Combaret, Valérie, Delattre, Olivier, Schleiermacher, Gudrun · 2018 · Clinical Cancer Research
Cited by 148

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Purpose: Neuroblastoma displays important clinical and genetic heterogeneity, with emergence of new mutations at tumor progression. Experimental Design: To study clonal evolution during treatment and follow-up, an innovative method based on circulating cell-free DNA (cfDNA) analysis by whole-exome sequencing (WES) paired with target sequencing was realized in sequential liquid biopsy samples of 19 neuroblastoma patients. Results: WES of the primary tumor and cfDNA at diagnosis showed overlap of single-nucleotide variants (SNV) and copy number alterations, with 41% and 93% of all detected alterations common to the primary neuroblastoma and cfDNA. CfDNA WES at a second time point indicated a mean of 22 new SNVs for patients with progressive disease. Relapse-specific alterations included genes of the MAPK pathway and targeted the protein kinase A signaling pathway. Deep coverage target sequencing of intermediate time points during treatment and follow-up identified distinct subclones. For 17 seemingly relapse-specific SNVs detected by cfDNA WES at relapse but not tumor or cfDNA WES at diagnosis, deep coverage target sequencing detected these alterations in minor subclones, with relapse-emerging SNVs targeting genes of neuritogenesis and cell cycle. Furthermore a persisting, resistant clone with concomitant disappearance of other clones was identified by a mutation in the ubiquitin protein ligase HERC2. Conclusions: Modelization of mutated allele fractions in cfDNA indicated distinct patterns of clonal evolution, with either a minor, treatment-resistant clone expanding to a major clone at relapse, or minor clones collaborating toward tumor progression. Identification of treatment-resistant clones will enable development of more efficient treatment strategies. Clin Cancer Res; 24(4); 939–49. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1586

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 148

Metadata

Authors
Chicard, M., Colmet-Daage, L., Clement, N., Danzon, A., Bohec, M., Bernard, V., Baulande, S., Bellini, A., Deveau, P., Pierron, G., Lapouble, E., Janoueix-Lerosey, I., Peuchmaur, M., Corradini, N., Defachelles, A. S., Valteau-Couanet, D., Michon, J., Combaret, V., Delattre, O., & Schleiermacher, G.
Venue
Clinical Cancer Research
Published
2018-02-14
Volume
24
Issue
4
Pages
939-949
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2774773003
Cited by
148
References
11
FWCI
8.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1586
The paper
Chicard, M., Colmet-Daage, L., Clement, N., Danzon, A., Bohec, M., Bernard, V., Baulande, S., Bellini, A., Deveau, P., Pierron, G., Lapouble, E., Janoueix-Lerosey, I., Peuchmaur, M., Corradini, N., Defachelles, A. S., Valteau-Couanet, D., Michon, J., Combaret, V., Delattre, O., & Schleiermacher, G. (2018). Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.